To play this presentation please log in.
Don't have an account?
Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.
Faculty
Eunice S Wang
MD
Roswell Park Comprehensive Cancer Center, Buffalo, New York
Chief, Leukemia/Benign Hematology Service, Professor of Oncology, Department of Medicine
TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia.
LEARNING OBJECTIVES
- Analyze patient-specific factors and available clinical trial data guiding the selection of induction therapy for patients with primary and secondary acute myeloid leukemia (AML) to optimize clinical and quality-of-life outcomes.
- Reflect on available research evidence with approved FLT3 inhibitors, and use this information to guide the clinical care of appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
- Understand available efficacy and safety data with IDH1 inhibitors for patients with IDH1-mutant AML, and integrate this novel approach into treatment algorithms.
- Recognize the scientific justification for the development of menin inhibitors for the treatment of certain genetically defined subsets of AML, and consider available research findings with and the current and potential role of these novel agents.
- Assess published research findings with oral hypomethylating agent therapy for patients with AML in order to determine the current and appropriate clinical application of this therapeutic approach.
- Recall new data with agents and strategies currently under investigation for AML, and discuss ongoing trial opportunities with eligible patients.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Video Interview: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Video Lecture: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) and 0.75 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY
To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:
Video Interview: ResearchToPractice.com/OncologyToday25/PostASCOEHAAML/Video and evaluation ResearchToPractice.com/OncologyToday25/PostASCOEHAAML/Video/CME.
Video Lecture: ResearchToPractice.com/OncologyToday25/PostASCOEHAAML/Presentation and evaluation ResearchToPractice.com/OncologyToday25/PostASCOEHAAML/Presentation/CME.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Eunice S Wang, MD
Chief, Leukemia/Benign Hematology Service
Professor of Oncology, Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Advisory Boards: AbbVie Inc, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo Inc, Dark Blue Therapeutics, Johnson & Johnson, Kite, A Gilead Company, Kura Oncology, Novartis, QIAGEN, Rigel Pharmaceuticals Inc, Ryvu Therapeutics, Schrödinger, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Kura Oncology, Menarini Group; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Gilead Sciences Inc; Speakers Bureaus: Astellas, Pfizer Inc; Nonrelevant Financial Relationships: UpToDate.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
These activities are supported by educational grants from Daiichi Sankyo Inc, Kura Oncology, Rigel Pharmaceuticals Inc, and Syndax Pharmaceuticals.
Release date: October 2025
Expiration date: October 2026
After completing the post-test, learners may download and review the answers here in order to identify further areas of study.
Aldoss I et al. Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in patients with relapsed or refractory (R/R) KMT2Ar acute leukemia. EHA 2025;Abstract PS1473.
Arellano ML et al. Patients with relapsed or refractory (R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML): Updated results from the phase 2 AUGMENT-101 study. EHA 2025;Abstract PS1467.
De Botton S et al. Effect of mutation type and co-mutations on response to olutasidenib in patients with relapsed/refractory mutated IDH1 AML. EHA 2025;Abstract PF516.
Erba H et al. Ziftomenib combined with intensive induction chemotherapy (7+3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia (AML): Updated phase 1a/b results from KOMET-007. EHA 2025;Abstract S136.
Fathi AT et al. Ziftomenib combined with venetoclax/azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Interim phase 1a results from KOMET‑007. ASH 2024;Abstract 2880.
Levis M et al. The combination of a FLT3-ITD, NPM1MUT and an epigenetic regulatory gene mutation confers unique sensitivity to quizartinib: Analysis from the QUANTUM-FIRST trial. EHA 2025;Abstract S140.
Marvin-Peek J et al. A phase IB/2 trial of an all-oral “triplet” regimen for IDH-mutated myeloid malignancies: Decitabine/cedazuridine and venetoclax in combination with ivosidenib/enasidenib. EHA 2025;Abstract PS1471.
Montesinos P et al. QuANTUM-Wild: A phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in FLT3-ITD–negative acute myeloid leukemia (AML). ASCO 2025;Abstract TPS6580.
Wang ES et al. A phase 2 study of olutasidenib in relapsed/refractory acute myeloid leukemia: Outcomes by number of prior treatment regimens. ASCO 2025;Abstract 6545.
Wang ES et al. Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study. ASCO 2025;Abstract 6506.
Wang ES et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol 2024;25(10):1310-24. Abstract
Wei AH et al. RP2D determination of bleximenib in combination with VEN+AZA: Phase 1b study in ND & R/R AML with KMT2A/NPM1 alterations. EHA 2025;Abstract S137.
Yilmaz M et al. Phase I/II study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AML. EHA 2025;Abstract S142.
Zeidan AM et al. An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts. ASCO 2025;Abstract 6504.
Zeidan AM et al. Registrational phase 3 study of ziftomenib in combination with non-intensive or intensive chemotherapy for newly diagnosed NPM1-m AND/OR KMT2A-r acute myeloid leukemia (AML): The KOMET-017 trial. EHA 2025;Abstract PB2573.
Zeidner J et al. Azacitidine, venetoclax, and revumenib for newly diagnosed older adults with acute myeloid leukemia (AML) and NPM1 mutation or KMT2A rearrangement: Updated results from the Beat AML consortium. EHA 2025;Abstract S138.